

RESOLUTION

Subject: Collaborative Drug Therapy Management

Submitted by: Michael Kuduk, MD (KMA Past President)

Referred to: Reference Committee

---

WHEREAS, physicians possess expertise in generating differential diagnoses, creating effective diagnostic and therapeutic plans, and utilization of deductive medical reasoning; and

WHEREAS, pharmacists possess expertise in pharmacology, pharmacokinetics, drug-drug interactions, and the ability to monitor ongoing therapy; and

WHEREAS, evidence shows that well designed collaborative drug therapy management programs utilize both physicians' and pharmacists' expertise to improve patient care (CDC August 2005); and

WHEREAS, evidence shows that physician-led team based care results in improved patient care outcomes and improved provider well-being (ACP Position Paper, 2025); now, therefore, be it

RESOLVED, that KMA reaffirms support for physician-led collaborative care agreements, which allow monitoring, modifying and discontinuing of a patient's drug therapy by an authorized pharmacist under the supervision of a physician in accordance with a collaborative care agreement and which do not have a diagnostic component.